Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09768068
Filing Date		2001-01-22
First Named Inventor	John	K. Gallant
Art Unit		2661
Examiner Name	P. Sa	ım .
Attorney Docket Number		RIC00018

				U.S.PATENTS		Hernove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines whe Relevant Passages or Rele Figures Appear		
	1	6754322		2004-06-22	Bushnell				
	2	6661882		2003-12-09	Muir et al.	Muir et al.			
	3	6141410		2000-10-31	Ginzboorg	Ginzboorg			
	4	6516350		2003-02-04	Lumelsky et a	al			
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	niner Cite No Publication Number Kind Code! Publication Name of Patentee or Application of cited Document			Releva	Columns,Lines where int Passages or Relev s Appear				
	1								
If you wisl	h to ac	dd additional U.S. Publis	shed Ap	plication citat	ion information	please click the Ada	d button	Add	_
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication e4 Date	Name of Patente Applicant of cited Document	e or V	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	-

U.S.PATENTS

| INFORMATION DISCLOSURE | Application Number | G6780808 | Filing Date | 2001-01-22 | Filing Date | 2001-01-22 | Filing Date | Art Unit | 2661 | 2001-01-23 | Filing Date | 2001-01-22 | Filing Date | 2001-01-22

	1											
If you wis	h to a	dd add	fitional Foreig	n Patent Doc	ument citati	on information	please d	ick the Add butto	n Add			
				NON-	PATENT L	TERATURE D	OCUMEN	ITS	Remo	ve		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher								Тs			
	1											
If you wish to add additional non-patent literature document citation information please click the Add button Add												
EXAMINER SIGNATURE												
Examiner	Signa	ature					Di	ate Considered				
*EXAMIN	ER: Ir	itial if	reference cor	nsidered, whe	ther or not	citation is in cor	nformano	e with MPEP 609	Draw I	ine thro	ough a	

See first Codes of USPTO Fleets Documents at sew USETO_DQLY or METE 961.04. * Enter of this issued the document, by the lock latter code (NRPO Standard ST.3). * For Lapranese patient document, the addition of the year of the night of the Emporer same process the seal number of the plant for which is standard ST.3. * For Emporer same process the seal number of the plant for which is standard ST.3. * For Emporer same process the seal number of the plant for the Emporer same process the seal number of the plant for the Emporer same process the seal number of the Emporer same process the seal number of the Emporer same process that the seal number of the Emporer same pr

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09768068		
Filing Date		2001-01-22		
First Named Inventor John		K. Gallant		
Art Unit		2661		
Examiner Name P. Sa		m		
Attorney Docket Number		RIC00018		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.981	to make the	appropriate	selection(s):
---------------	----------	-----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no tern of information contained in the information disclosure statement was cled in a communication from a orieign patient office in a counterpart foreign application, and, to the knowledge of the person signing the centification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual decinization if 20 CPR 1.55(c) more than three months onto to the filling of the information disclosure.

- statement. See 37 CFR 1.97(e)(2).

 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	om of the agrantee.							
	Signature	/Eden U.I. Stright/	Date (YYYY-MM-DD)	2006-04-04				
	Name/Print	Eden U.I. Stright	Registration Number	51205				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.231-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. (2)(2)(2) farmishing of the information solicide to is columbary, and (3) the primoral pursues for which the information is used by the U.S. Patient and Trademan (Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested requirement of the patient of the patient application or patient. If you do not furnish the requested requirement of the patient application or patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C.552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- . A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application part to published application, an application part to put to published application, an application.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.